Longbio-b
1779.HK
Hong Kong Stock Exchange142.80
HKD
-1.10
- -
ISIN
CNE100007NF2
Return %
Stock
S&P500
1Y
8.35
24.99
3Y
8.35
70.19
5Y
8.35
77.45
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Heng Liu
- Full Time Employees
- 85
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building F, Area A Suzhou People's Republic of China 215500
- IPO Date
- Jun 5, 2026
- Website
- longbio.com
- Similar Companies
- Business
- LongBio Pharma (Suzhou) Co., Ltd. engages in in-house discovery and development of biopharmaceuticals targeting allergic and autoimmune diseases, with an emphasis on innovative biologics across multiple therapeutic areas. The company operates a diversified pipeline including LP-003, an anti-IgE antibody in late-stage development; LP-005, a bifunctional antibody fusion protein; LP-00A, a bi-functional antibody for allergic diseases; LP-00C, a bi-functional antibody or fusion protein for B-cell mediated autoimmune diseases; and LP-00D, a tissue- and organ-targeted complement inhibitor. LongBio-B positions itself as a clinical-stage biopharmaceutical company leveraging proprietary discovery platforms to advance biologics for rhinology, dermatology, respiratory, hematology, nephrology, and miscellaneous autoimmune indications. Headquartered in Shanghai, with additional operations in Changshu, Suzhou, China, the company focuses on in-house research and development, early to mid-stage clinical testing, and preparation for regulatory submissions, including anticipated BLA activities in the near term. LongBio-B aims to deliver affordable, high-quality biologic medicines to patients and to expand its footprint through strategic collaborations, pipeline expansions, and potential future commercialization partnerships in China and internationally. The company’s recent public listing activity on the Hong Kong Stock Exchange under the ticker 1779.HK reflects its ongoing growth trajectory and commitment to scaling its biopharmaceutical portfolio.